AU2012329274B2 - Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies - Google Patents
Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies Download PDFInfo
- Publication number
- AU2012329274B2 AU2012329274B2 AU2012329274A AU2012329274A AU2012329274B2 AU 2012329274 B2 AU2012329274 B2 AU 2012329274B2 AU 2012329274 A AU2012329274 A AU 2012329274A AU 2012329274 A AU2012329274 A AU 2012329274A AU 2012329274 B2 AU2012329274 B2 AU 2012329274B2
- Authority
- AU
- Australia
- Prior art keywords
- disease
- amyloid
- compounds
- compound
- synuclein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552077P | 2011-10-27 | 2011-10-27 | |
| US61/552,077 | 2011-10-27 | ||
| PCT/US2012/059481 WO2013062762A1 (en) | 2011-10-27 | 2012-10-10 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012329274A1 AU2012329274A1 (en) | 2014-04-17 |
| AU2012329274B2 true AU2012329274B2 (en) | 2016-11-10 |
Family
ID=48168320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012329274A Ceased AU2012329274B2 (en) | 2011-10-27 | 2012-10-10 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9169255B2 (https=) |
| EP (1) | EP2753333B1 (https=) |
| JP (1) | JP6095072B2 (https=) |
| CN (1) | CN104010641B (https=) |
| AU (1) | AU2012329274B2 (https=) |
| CA (1) | CA2853633A1 (https=) |
| WO (1) | WO2013062762A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001371B (zh) * | 2014-10-09 | 2019-07-05 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
| NZ746901A (en) * | 2016-03-11 | 2023-06-30 | Ac Immune Sa | Bicyclic compounds for diagnosis and therapy |
| IL269550B2 (en) | 2017-03-27 | 2025-01-01 | Chase Therapeutics Corp | Combining a 5HT3 antagonist and pramipexole for the treatment of synucleinopathies |
| EP3388432A1 (en) | 2017-04-10 | 2018-10-17 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders |
| CN113573708A (zh) * | 2019-02-07 | 2021-10-29 | 阿尔萨泰克公司 | 艾莫西平多价衍生物 |
| WO2023023867A1 (en) * | 2021-08-26 | 2023-03-02 | Mcmaster University | Compounds for reducing cholesterol and treating liver and kidney disease |
| CN115997722A (zh) * | 2022-12-26 | 2023-04-25 | 海南大学 | Aβ42-hIAPP共寡聚化物诱导的AD非人灵长类动物模型方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003101927A1 (en) * | 2002-05-31 | 2003-12-11 | Proteotech, Inc. | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease |
| US20050261316A1 (en) * | 2002-11-08 | 2005-11-24 | Rao Kalla | A2B Adenosine receptor antagonists |
| EP1808169A2 (en) * | 1999-12-30 | 2007-07-18 | Proteotech Inc. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| US20090042940A1 (en) * | 2002-05-17 | 2009-02-12 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20090076019A1 (en) * | 2006-10-13 | 2009-03-19 | Mount Sinai Hospital | Methods for treating neurological disorders or damage |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000069464A1 (en) * | 1999-05-12 | 2000-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Novel use |
| DK1444233T3 (da) * | 2001-11-09 | 2011-10-17 | Gilead Palo Alto Inc | A2B-adenosinreceptorantagonister |
| US20080226715A1 (en) * | 2007-03-16 | 2008-09-18 | Albert Cha | Therapeutic compositions and methods |
-
2012
- 2012-10-10 CA CA2853633A patent/CA2853633A1/en not_active Abandoned
- 2012-10-10 WO PCT/US2012/059481 patent/WO2013062762A1/en not_active Ceased
- 2012-10-10 AU AU2012329274A patent/AU2012329274B2/en not_active Ceased
- 2012-10-10 US US14/238,755 patent/US9169255B2/en not_active Expired - Fee Related
- 2012-10-10 CN CN201280051004.1A patent/CN104010641B/zh not_active Expired - Fee Related
- 2012-10-10 JP JP2014538819A patent/JP6095072B2/ja not_active Expired - Fee Related
- 2012-10-10 EP EP12842836.4A patent/EP2753333B1/en not_active Not-in-force
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1808169A2 (en) * | 1999-12-30 | 2007-07-18 | Proteotech Inc. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| US20090042940A1 (en) * | 2002-05-17 | 2009-02-12 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| WO2003101927A1 (en) * | 2002-05-31 | 2003-12-11 | Proteotech, Inc. | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease |
| US20050261316A1 (en) * | 2002-11-08 | 2005-11-24 | Rao Kalla | A2B Adenosine receptor antagonists |
| US20090076019A1 (en) * | 2006-10-13 | 2009-03-19 | Mount Sinai Hospital | Methods for treating neurological disorders or damage |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2753333B1 (en) | 2017-06-21 |
| CN104010641B (zh) | 2017-04-12 |
| NZ623046A (en) | 2015-12-24 |
| WO2013062762A1 (en) | 2013-05-02 |
| JP2014532643A (ja) | 2014-12-08 |
| JP6095072B2 (ja) | 2017-03-15 |
| CN104010641A (zh) | 2014-08-27 |
| US9169255B2 (en) | 2015-10-27 |
| AU2012329274A1 (en) | 2014-04-17 |
| EP2753333A1 (en) | 2014-07-16 |
| EP2753333A4 (en) | 2015-01-28 |
| US20140194447A1 (en) | 2014-07-10 |
| CA2853633A1 (en) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012329274B2 (en) | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | |
| EP2328417B1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF beta-AMYLOID DISEASES AND SYNUCLEINOPATHIES | |
| US7919530B2 (en) | Compounds, compositions, and methods for the treatment of synucleinopathies | |
| EP2527315B1 (en) | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease | |
| US20180002298A1 (en) | Compounds for the treatment of neurodegenerative diseases | |
| EP1751097B1 (en) | Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | |
| NZ623046B2 (en) | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | |
| US8916598B2 (en) | Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies | |
| US20100331380A1 (en) | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |